<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0003972" disease_type="Disease or Syndrome" abbrv="ascvd">Atherosclerotic cardiovascular disease</z:e> remains a major cause of mortality and morbidity in most developed countries </plain></SENT>
<SENT sid="1" pm="."><plain>Experimental and clinical evidence suggests that <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitors</z:chebi> and vitamin E therapy may retard the atherosclerotic process; however, definitive proof in humans is lacking </plain></SENT>
<SENT sid="2" pm="."><plain>The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with <z:chebi fb="0" ids="8774">Ramipril</z:chebi> and Vitamin E (SECURE) is designed to assess the effects of <z:chebi fb="0" ids="8774">ramipril</z:chebi>--an <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitor</z:chebi>, at 2 doses: 2.5 mg daily (which has little effect on lowering blood pressure) and 10 mg daily--and the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> vitamin E, 400 IU daily, on <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> progression in 732 patients using a factorial 3 x 2 study design </plain></SENT>
<SENT sid="3" pm="."><plain>High-risk patients with a documented history of significant <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> or with <z:mp ids='MP_0002055'>diabetes</z:mp> and additional risk factors were enrolled and will be followed for 4 years </plain></SENT>
<SENT sid="4" pm="."><plain>The extent and progression of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> are assessed noninvasively by B-mode carotid ultrasonography </plain></SENT>
<SENT sid="5" pm="."><plain>The SECURE trial is a substudy of the larger Heart Outcomes Prevention Evaluation (HOPE) study of 9,541 high-risk patients evaluating the effects of <z:chebi fb="0" ids="8774">ramipril</z:chebi> and vitamin E on major cardiovascular events (cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, and <z:hpo ids='HP_0001297'>stroke</z:hpo>) </plain></SENT>
<SENT sid="6" pm="."><plain>The 2 studies are complementary </plain></SENT>
<SENT sid="7" pm="."><plain>Whereas HOPE is expected to provide information on major clinical outcomes, SECURE will shed light on the mechanisms by which these effects may be mediated </plain></SENT>
</text></document>